Supermarkets will cease the sale of Bonjela Teething Gel and Bonjela Mouth Ulcer Gel starting from 1 October.
This decision comes after the Therapeutic Goods Administration (TGA) reclassified the products from Schedule 1 to Schedule 2 medicines due to concerns about toxicity levels resulting from misuse. However, the gels will still be available for purchase in pharmacies.
The reclassification comes as a response to growing worries about the potential toxicity of Bonjela’s active ingredient, choline salicylate, which is a non-steroidal anti-inflammatory (NSAID).
Excessive use of the product can lead to toxicity. Symptoms of choline salicylate overdose may include unusual sleepiness, fever, and rapid breathing.
The manufacturer of Bonjela, Reckitt, assures consumers that their products are safe and effective when used according to the label instructions.
Those recommended usage guidelines are that only a pea-sized amount should be applied, and this can be repeated every three hours if necessary. However, it is important not to exceed the maximum of six doses in a 24-hour period.
Do you use Bonjela?
.
